GLP-1药物在降低肥胖相关癌症风险方面优于胰岛素
GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments
一项研究分析了359,595名糖尿病患者使用GLP-1受体激动剂与使用胰岛素或磺脲类药物相比,肥胖相关癌症的风险。结果显示,使用GLP-1药物的患者在三年内患肥胖相关癌症的风险较低,但不同糖尿病严重程度下的效果不同。
研究发现GLP-1药物在降低肥胖相关癌症风险方面优于胰岛素,但不同糖尿病严重程度下的效果不同。
Years of research point to obesity and type 2 diabetes raising the risk of developing several types of cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recent medical breakthrough, were originally developed for blood sugar control or diabetes management and also work overtime promoting weight loss. Scientists are curious to explore whether there are any links between these drugs and the onset of cancers in people with diabetes.
A recent study published in JAMA Network Open examined the risk of developing obesity-related cancers among patients starting on GLP-1 receptor agonists, compared with other common diabetes medications—metformin, insulin, sulfonylureas, SGLT2 inhibitors and DPP-4 inhibitors.
The researchers analyzed electronic health records of 359,595 adults treated at UT Southwestern Medical Center between Jan. 1, 2010, and July 31, 2025. From this pool, they identified patients who fit the criteria and then tracked them for three to five years. They considered the first occurrence of any obesity-related cancer as the study's primary outcome.
Patients who started GLP-1 drugs had a lower risk of developing obesity-related cancers over three years than those who began treatment with insulin or sulfonylureas. The difference in estimated cancer risk was 1.25 percentage points compared with insulin and 1.14 percentage points compared with sulfonylureas.
Closer look at cancer risk
In patients with type 2 diabetes, doctors choose a medication based on a patient's preexisting complications. Those with more advanced diabetes or kidney and blood vessel damage are often prescribed treatments like insulin later in their disease course, while others are prescribed metformin or SGLT2 inhibitors based on their blood sugar levels and needs.
Recently, doctors have also started to prescribe GLP-1 RAs, which mimic a natural hormone released from the gut after eating to regulate blood sugar and appetite. These agonists activate the same GLP-1 receptors in the stomach that not only slow down stomach emptying but also signal the pancreas to release insulin when blood sugar levels rise.
The medications doctors prescribe, and the complications they aim to manage, could also shape a patient's cancer risk. Researchers in this study set out to see whether starting GLP-1 drugs was linked to a different risk of obesity-related cancers than starting other diabetes medications, and whether this association varied with the severity of patients' diabetes.
They adopted a study framework called target trial emulation, which was designed to mimic the rigor of randomized clinical trials using real-world medical records. They sifted through 15 years of electronic health records to identify adults with type 2 diabetes who had no previous history of obesity-related cancer.
To capture the effects of starting a new treatment rather than continuing long-term medication, they also required patients to have gone at least 365 days without taking the specific drug before beginning it. This one-year gap was known as the washout period.
The team set up head-to-head comparisons between GLP-1 injections and the five drugs. Since existing complications can influence both a doctor's choice of medication and a patient's cancer risk, the team divided participants into three groups based on diabetes severity, from low to high.
They tracked each patient from the day they started the medication until they developed an obesity-related cancer, died, attended their last clinic visit, reached the study's cutoff date, or completed three or five years of follow-up.
Diabetes severity matters
Patients starting GLP-1 receptor agonists were less likely to develop obesity-related cancers than those starting insulin or sulfonylureas. However, comparisons with metformin, SGLT2 inhibitors and DPP-4 inhibitors showed no statistically significant differences in cancer incidence over three or five years.
The association between GLP-1 drugs and lower obesity-related cancer risk was strongest in patients with less severe diabetes and no major complications. Among those with severe diabetes, including macrovascular disease or advanced kidney disease, the differences between GLP-1 agonists and insulin or sulfonylureas were no longer statistically significant. For these patients, SGLT2 inhibitors were linked to a lower three-year cancer risk than GLP-1 drugs.
The findings offered one major reassurance: GLP-1 receptor agonists do not increase obesity-related cancer risk. While the results look promising for certain cases, the authors emphasize that these results do not support prescribing GLP-1 drugs for cancer prevention. They suggest the patterns may reflect both how patients were selected for treatment and how severe their underlying disease was.
Written for you by our author Sanjukta Mondal, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.
Publication details
Jesús Gibran Hernández-Pérez et al., GLP-1 Receptor Agonists and Obesity-Related Cancer by Diabetes Severity, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.41869
Journal information: JAMA Network Open
Who's behind this story?
Sanjukta Mondal
Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
© 2026 Science X Network
Citation: GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-glp-drugs-obesity-cancer-insulin.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com